Unknown

Dataset Information

0

Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.


ABSTRACT:

Background

We conducted double-blind, placebo-controlled trials assessing the efficacy and tolerability of favipiravir in acute influenza.

Methods

Otherwise healthy adults with influenza-like symptoms and fever of ≤48 hours were randomized to favipiravir (1800 mg twice daily [BID] on day 1, 800 mg BID on days 2-5) or placebo tablets (1:1 in US316; 3:1 in US317). The primary efficacy endpoint was the time to illness alleviation when 6 influenza symptoms were self-rated as absent or mild and fever was absent in the intention-to-treat, influenza-infected participants.

Results

In US316 (301 favipiravir, 322 placebo), favipiravir was associated with a 14.4-hour reduction (median, 84.2 vs 98.6 hours; P = .004) in time to illness alleviation vs placebo. In US317 (526 favipiravir, 169 placebo), favipiravir did not significantly reduce time to alleviation (median, 77.8 vs 83.9 hours). In both trials favipiravir was associated with reduced viral titers, RNA load area under the curve over days 1-5, and median times to cessation of virus detection (P < .001). Aside from asymptomatic hyperuricemia, no important differences in adverse events were found.

Conclusions

This favipiravir dosing regimen demonstrated significant antiviral efficacy but inconsistent illness alleviation in uncomplicated influenza. Studies of higher doses and antiviral combinations for treating serious influenza and other RNA viral infections are warranted. Clinical Trials Registration. NCT02026349; NCT02008344.

SUBMITTER: Hayden FG 

PROVIDER: S-EPMC9650493 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.

Hayden Frederick G FG   Lenk Robert P RP   Stonis Lucille L   Oldham-Creamer Catherine C   Kang Lih Lisa LL   Epstein Carol C  

The Journal of infectious diseases 20221101 10


<h4>Background</h4>We conducted double-blind, placebo-controlled trials assessing the efficacy and tolerability of favipiravir in acute influenza.<h4>Methods</h4>Otherwise healthy adults with influenza-like symptoms and fever of ≤48 hours were randomized to favipiravir (1800 mg twice daily [BID] on day 1, 800 mg BID on days 2-5) or placebo tablets (1:1 in US316; 3:1 in US317). The primary efficacy endpoint was the time to illness alleviation when 6 influenza symptoms were self-rated as absent or  ...[more]

Similar Datasets

| S-EPMC6412085 | biostudies-literature
| S-EPMC7164783 | biostudies-literature
| S-EPMC9047233 | biostudies-literature
| S-EPMC10851846 | biostudies-literature
| S-EPMC6476494 | biostudies-literature
| S-EPMC8801227 | biostudies-literature
| S-EPMC5521248 | biostudies-literature
| S-EPMC8747778 | biostudies-literature
| S-EPMC10364767 | biostudies-literature